Opinion|Videos|December 20, 2024
Early Intervention in High-Risk Smoldering Myeloma: Results From the AQUILA Study at ASH 2024
Author(s)Saad Z. Usmani, MD, MBA, FACP, FASCO
Saad Z. Usmani, MD, MBA, FACP, discusses how the AQUILA study data presented at ASH 2024, highlighting the benefits of early intervention in high-risk smoldering multiple myeloma, could impact treatment strategies by improving progression-free survival, while also addressing potential drawbacks of intervening too early in the disease course.
Advertisement
Video content above is prompted by the following:
- Coming into ASH 2024, what would did consider to be the largest unmet need in the treatment and management of multiple myeloma?
- Discuss the data presented at the 2024 ASH Annual Meeting from the AQUILA study in high-risk smoldering multiple myeloma. (
Abstract ) - What was the objective of this study?
- How was this study designed/what methodology was used?
- What results were presented?
- Primary end point: progression-free survival, median not reached for daratumumab vs 41.5 for active observation
- What are your key takeaways from this study, and how might this data impact the way high-risk smoldering multiple myeloma is managed?
- What potential drawbacks could arise from intervening this early in the disease course of multiple myeloma?
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Related Content
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Government Shutdown Could Disrupt Health Care Access
2
Maternal, Child Mortality Higher in the US Compared With Majority of High-Income Countries
3
Most Medicare Beneficiaries Find Plan Shopping Confusing, Survey Finds
4
Lurbinectedin Combo Approved by FDA for Extensive-Stage Small Cell Lung Cancer
5
